急诊尿激酶静脉溶栓对急性心肌梗死临床治疗价值研究.docVIP

急诊尿激酶静脉溶栓对急性心肌梗死临床治疗价值研究 　　[摘要] 目的：探讨尿激酶静脉溶栓治疗对急性心肌梗死的临床应用价值。方法：选取本院2004～2009年采用尿激酶静脉溶栓进行急性心肌梗死治疗的117例患者，按溶栓距发病时间6 h为界限，分为观察组和对照组，对两组患者的治疗情况进行总结。结果：观察组中血管再通率达84.7%，高于对照组53.4%的血管再通率。观察组中仅有2例死亡，对照组8例死亡，两组比较差异有统计学意义，χ2=13.45，P0.01。结论：尿激酶静脉溶栓对急性心肌梗死的治疗有较好的临床效果，尽快进行尿激酶静脉溶栓治疗可大幅度提高血管再通率，降低死亡率，使患者生命安全得到更好的保障。 　　[关键词] 尿激酶静脉溶栓；急性心肌梗死；临床研究 　　[中图分类号] R542.2+2 [文献标识码]A[文章编号]1674-4721（2011）04（c）-030-02 　　 　　Value of emergency intravenous thrombolysis with urokinase for treatment of acute myocardial infarction 　　FAN Zechao 　　The Honor Military Rehabilitation Hospital in Guangdong Province, Guangzhou 510260, China 　　[Abstract] Objective: To investigate the clinical applications value of urokinase thrombolytic therapy for acute myocardial infarction. Methods: To select 117 acute myocardial infarction patients treated by urokinase intravenous thrombolysis from 2004 to 2009 in our hospital. Thrombolysis to the time of onset was 6 hours as the limit, all patients were divided into observation group and control group, to summarize the treatment of two groups. Results: The rate of recanalization in observation group(84.7%) was higher than control group (53.4%). And only 2 deaths in observation group, 8 deaths in control group, the number of deaths was also less than the control group, differences were significant between the two groups, χ2= 13.45, P0.01. Conclusion: Urokinase thrombolytic therapy of acute myocardial infarction have better clinical results, as soon as possible urokinase thrombolytic therapy can greatly improve the recanalization rate, lower mortality, so that patients receive better protection of life safety. 　　[Key words] Urokinase thrombolysis; Acute myocardial infarction; Clinical research 　　 　　尿激酶是从健康人尿中分离或从人体肾组织中培养获得的一种酶蛋白。尿激酶可作用于纤溶酶原，使其转化为纤溶酶，达到溶解血栓的目的。应用尿激酶静脉溶栓对急性心肌梗死患者进行治疗，有较好的治疗效果和临床价值。 　　1 资料与方法 　　1.1 一般资料 　　选取本院2004～2009年间采用尿激酶静脉溶栓进行急性心肌梗塞治疗的117例患者，按溶栓距发病时间6 h为界限，分为观察组和对照组。溶栓时间距发病时间6 h内的患者作为观察组，共59例，男46例，女13例，年龄37～81岁，平均57.2岁，梗死部位前壁16例，下壁14例，前间壁